Kiniksa Pharmaceuticals (KNSA) Receives a Buy from Goldman Sachs

Goldman Sachs analyst Paul Choi maintained a Buy rating on Kiniksa Pharmaceuticals (KNSA – Research Report) today. The company’s shares opened today at $19.51.

Choi covers the Healthcare sector, focusing on stocks such as PTC Therapeutics, Ascendis Pharma, and Kiniksa Pharmaceuticals. According to TipRanks, Choi has an average return of 8.0% and a 55.68% success rate on recommended stocks.

Currently, the analyst consensus on Kiniksa Pharmaceuticals is a Strong Buy with an average price target of $27.00.

The company has a one-year high of $22.09 and a one-year low of $10.29. Currently, Kiniksa Pharmaceuticals has an average volume of 407.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Kiniksa Pharmaceuticals (KNSA) Company Description:

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, KPL-716, KPL-045, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason, and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Hamilton, Bermuda.